C22.0
Liver cell carcinoma
Clinical Classification Guidelines
Inclusion Terms
- Hepatocellular carcinoma
- Hepatoma
Medical Intelligence & Overview
Liver cell carcinoma, also known as hepatocellular carcinoma or hepatoma, is a primary malignant tumor of the liver. It originates in the liver cells and is among the most common types of liver cancer worldwide. This condition often develops in the context of chronic liver disease and cirrhosis, making early diagnosis and understanding vital for management and treatment options.
Causes & Symptoms
Clinical Causes: Chronic hepatitis B or C infection Cirrhosis of the liver caused by alcohol abuse or other factors Non-alcoholic fatty liver disease (NAFLD) Exposure to aflatoxins (toxins from certain molds found in food) Family history of liver cancer Certain inherited metabolic diseases such as hemochromatosis Long-term exposure to toxins or chemicals
Key Symptoms: Unintended weight loss Persistent abdominal pain or discomfort Swelling or a feeling of fullness in the abdomen Jaundice (yellowing of the skin and eyes) Nausea or vomiting A lump or mass in the upper right portion of the abdomen Weakness and fatigue Loss of appetite
Diagnostic & Treatment
Diagnosis Path: The diagnosis of liver cell carcinoma typically involves a combination of medical history, physical examination, imaging tests, and laboratory studies: - **Blood tests** to check liver function and tumor markers such as alpha-fetoprotein (AFP) - **Imaging scans**, including ultrasound, CT (computed tomography), and MRI (magnetic resonance imaging), to visualize the liver and detect tumors - **Biopsy**, where a small sample of liver tissue is examined microscopically to confirm malignancy - Additional tests may include blood clotting studies and assessments of liver cirrhosis severity
Treatment Protocols: Treatment options depend on the size, number, location of tumors, overall liver function, and the patient’s health status: - **Surgical resection**, where the tumor and part of the liver are removed if feasible - **Liver transplantation** for eligible candidates, offering the chance to remove both the tumor and underlying disease - **Local ablative therapies** such as radiofrequency ablation (RFA) and microwave thermotherapy - **Transarterial therapies**, including chemoembolization (TACE) and radioembolization, to cut off blood supply to the tumor - **Targeted drug therapies** like sorafenib for advanced cases - **Symptom management** and supportive care to improve quality of life The prognosis varies based on early detection and the extent of disease at diagnosis.
Clinical Advice & FAQs
Billing Guidance
Is C22.0 a billable ICD-10 code?
Yes, C22.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C22.0?
Clinical documentation must specify the nature of Liver cell carcinoma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
